Skip to main
TOI
TOI logo

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The Oncology Institute Inc. has demonstrated significant revenue growth, achieving year-over-year increases of 24%, 28%, and 21% from 2022 to 2024, coinciding with an expansion in the number of clinics under management from 67 to 86. The overall oncology market in the U.S. is substantial, exceeding $200 billion, with projections indicating a continued rise in oncology drug expenditures at a compound annual growth rate (CAGR) of over 10%. With anticipated strong growth in key markets like Nevada and Florida, alongside robust dispensing revenue and margin expansion due to better utilization of existing capacity, the outlook for the company remains favorable.

Bears say

The Oncology Institute Inc. has recently experienced a significant decline in revenue contribution from HUM, dropping from 20% to less than 10%, raising concerns about its financial stability. Additionally, investor apprehensions regarding cash levels nearing the $40 million minimum covenant threshold have placed downward pressure on TOI's stock in 4Q24. Lastly, the company's anticipated revenue trends appear to be well below the industry average, potentially creating further headwinds for growth in 2026 and 2027.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.